Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO regimen in elderly frail non-GCB DLBCL
NCT06530511Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Aug 2024
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin and orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Affiliated Hospital of Nantong University. Primary endpoint: Complete Response Rate at 6 months. Started Aug 2024; status: recruiting.
02
Drugs
polatuzumab vedotinorelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06530511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530511.